Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.

González A, Moniche F, Cayuela A, García-Lozano JR, Torrecillas F, Escudero-Martínez I, Gonzalez-Marcos JR, Mayol A, Montaner J.

Eur J Vasc Endovasc Surg. 2016 Feb;51(2):175-86. doi: 10.1016/j.ejvs.2015.09.020. Epub 2015 Oct 31.

PMID:
26526111
2.

Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.

Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K, Vlasis K, Vavuranakis M, Stone PH, Papavassiliou AG, Tousoulis D.

Atherosclerosis. 2015 Sep;242(1):102-8. doi: 10.1016/j.atherosclerosis.2015.07.009. Epub 2015 Jul 11.

PMID:
26188531
3.

Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.

Wei YQ, Wang DG, Yang H, Cao H.

PLoS One. 2015 Jul 6;10(7):e0132561. doi: 10.1371/journal.pone.0132561. eCollection 2015.

4.

Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers.

Shahabi P, Cuisset T, Stathopoulou MG, Morange PE, Grosdidier C, Herbeth B, Siest G, Alessi MC, Visvikis-Siest S.

Pharmacogenomics. 2015;16(5):459-69. doi: 10.2217/pgs.15.17.

PMID:
25916518
5.

Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel.

Li S, Shi Y, Wang H, Zhang W, Liu J.

J Thromb Thrombolysis. 2015 Jul;40(1):88-96. doi: 10.1007/s11239-015-1207-5.

PMID:
25800884
6.

Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.

Ichikawa M, Takei Y, Hamasaki T, Kijima Y.

Circ J. 2015;79(1):85-90. doi: 10.1253/circj.CJ-14-0639. Epub 2014 Oct 30.

7.

Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.

Kupstyte N, Zaliunas R, Tatarunas V, Skipskis V, Zaliaduonyte-Peksiene D, Grabauskyte I, Dovidaitiene D, Bumblauskas K, Gustiene O, Lesauskaite V.

Pharmacogenomics. 2015;16(3):181-9. doi: 10.2217/pgs.14.165.

8.

Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.

Nooney VB, Hurst NL, Chirkov YY, De Caterina R, Horowitz JD.

Vascul Pharmacol. 2015 Feb-Mar;65-66:17-22. doi: 10.1016/j.vph.2014.11.003. Epub 2014 Nov 20.

PMID:
25460367
9.

Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.

Park Y, Jeong YH, Tantry US, Ahn JH, Kim KH, Koh JS, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA.

Thromb Haemost. 2014 Dec;112(6):1198-208. doi: 10.1160/TH14-01-0040. Epub 2014 Aug 28.

PMID:
25182660
10.
11.

Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.

Mizobe M, Hokimoto S, Akasaka T, Arima Y, Kaikita K, Morita K, Miyazaki H, Oniki K, Nakagawa K, Ogawa H.

Thromb Res. 2014 Jul;134(1):72-7. doi: 10.1016/j.thromres.2014.04.020. Epub 2014 Apr 26.

PMID:
24821368
12.

CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention.

Zou JJ, Chen SL, Fan HW, Tan J, He BS, Xie HG.

J Cardiovasc Pharmacol. 2014 Feb;63(2):178-83. doi: 10.1097/FJC.0000000000000037.

PMID:
24508947
13.

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.

Hokimoto S, Mizobe M, Akasaka T, Arima Y, Kaikita K, Nakagawa K, Ogawa H.

Thromb Res. 2014 Apr;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003. Epub 2014 Jan 9.

PMID:
24440142
14.

The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment.

Lin YJ, Li JW, Zhang MJ, Qian L, Yang WJ, Zhang CL, Shao Y, Zhang Y, Huang YJ, Xu Y.

CNS Neurosci Ther. 2014 Feb;20(2):125-30. doi: 10.1111/cns.12173. Epub 2013 Dec 12.

PMID:
24330577
15.

Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.

JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

16.

What's new about clopidogrel.

Cialdella P, Gustapane M, Camaioni C, Biasucci LM.

Minerva Cardioangiol. 2013 Dec;61(6):683-9. Review.

PMID:
24253460
17.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

18.

Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.

Nishio R, Shinke T, Otake H, Nakagawa M, Inoue T, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Kuroda M, Hirata K.

Thromb Res. 2013 Nov;132(5):558-64. doi: 10.1016/j.thromres.2013.09.008. Epub 2013 Sep 13.

PMID:
24080149
19.

Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.

Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K.

J Cardiol. 2013 Sep;62(3):158-64. doi: 10.1016/j.jjcc.2013.03.006. Epub 2013 Jul 22.

20.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk